A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet

MeSH terms

• Adenine / administration & dosage
• Adenine / adverse effects
• Adenine / analogs & derivatives*
• Adenine / pharmacokinetics
• Administration, Oral
• Adult
• Aged
• Cross-Over Studies
• Deoxycytidine / administration & dosage
• Deoxycytidine / adverse effects
• Deoxycytidine / analogs & derivatives*
• Deoxycytidine / pharmacokinetics
• Drug Combinations
• Drug Compounding / methods*
• Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
• Female
• Humans
• Male
• Middle Aged
• Organophosphonates / administration & dosage
• Organophosphonates / adverse effects
• Organophosphonates / pharmacokinetics*
• Oxazines / administration & dosage
• Oxazines / adverse effects
• Oxazines / pharmacokinetics*
• Reverse Transcriptase Inhibitors / administration & dosage
• Reverse Transcriptase Inhibitors / adverse effects
• Reverse Transcriptase Inhibitors / pharmacokinetics*
• Tablets / administration & dosage
• Tablets / adverse effects
• Tablets / pharmacokinetics*
• Therapeutic Equivalency
• Treatment Outcome
• Water